Patency at 30 days · thrombosed haemodialysis arteriovenous fistulas and grafts
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patency at 30 days · thrombosed haemodialysis arteriovenous fistulas and grafts
It is very uncertain whether continuous Infusion changes patency at 30 days compared with pulse spray technique (very low certainty).
1 finding from 1 review
Patency at 30 days · thrombosed haemodialysis arteriovenous fistulas and grafts
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patency at 30 days · thrombosed haemodialysis arteriovenous fistulas and grafts
It is very uncertain whether surgical thrombectomy changes patency at 30 days compared with different types of endovascular interventions (very low certainty).
1 finding from 1 review
Patency at 30 days · thrombosed haemodialysis arteriovenous fistulas and grafts
It is very uncertain whether surgical thrombectomy changes patency at 30 days compared with mechanical thrombectomy (very low certainty).
1 finding from 1 review
Duration of hospital admission (days) · children with medical complexity
1 finding from 1 review
Intervention not reported
Death from bleeding complications (up to 30 days · vascular surgery patients who undergo creation of an anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Postoperative bleeding (up to 30 days · vascular surgery patients who undergo creation of an anastomosis
The intervention showed no clear difference in postoperative bleeding (up to 30 days (low certainty).
1 finding from 1 review
Intervention not reported
Unplanned return to the operating room (up to 30 days · vascular surgery patients who undergo creation of an anastomosis
The intervention showed no clear difference in unplanned return to the operating room (up to 30 days (low certainty).
1 finding from 1 review
Frequency of crisis (number of pain days) · sickle cell disease
N‐acetylcysteine (1200 mg) showed no clear difference in frequency of crisis (number of pain days) compared with placebo (low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · sickle cell disease
N‐acetylcysteine (1200 mg) showed no clear difference in severity of pain (maximum pain intensity on pain days) compared with placebo (low certainty).
1 finding from 1 review
Frequency of hospitalization (number of days in hospital) · sickle cell disease
It is very uncertain whether L‐arginine changes frequency of hospitalization (number of days in hospital) compared with placebo (very low certainty).
1 finding from 1 review
Energy intake · adults
1 finding from 1 review
Duration of cold symptoms (days) · adults and children without colds
1 finding from 1 review
Duration of cold symptoms (days) · adults and children with colds and/or upper respiratory infections
1 finding from 1 review
Intervention not reported
Intended and unintended consequences: social and institutional consequences ‐ days of absences avoided
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Length of hospital stay · adults with uncomplicated appendicitis
It is very uncertain whether antibiotics changes length of hospital stay (days) compared with surgery (very low certainty).
1 finding from 1 review
Number of drinks per day ‐ total · stopping or reducing alcohol consumption during pregnancy
1 finding from 1 review
Clinical remission · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes clinical remission (14 days) compared with placebo (very low certainty).
1 finding from 1 review
Clinical improvement (partial Mayo score) (60 days) · people with histologically confirmed diagnosis of ulcerative colitis in remission
1 finding from 1 review